Abstract
PURPOSE: Ambrisentan is a highly selective oral endothelin receptor antagonist (ERA) shown to improve exercise capacity and delay clinical worsening in pulmonary arterial hypertension (PAH). Little is known of its effects on right heart structure and function with long-term therapy. We evaluated right-sided cardiac variables from surveillance echocardiograms and 6-minute walk distance (6MWD) in patients on maximum therapy.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
